AdARRC™
  • Call Us: +971 2 245 0058
  • Email Us : info@adarrc.org
  • Home
  • About Us
  • Committee
  • Future Dates of AdARRC™
  • History
    • AdARRC Academy™
    • AdARRC Summit™
    • Previous Speakers of AdARRC™
  • Annual Initiatives
    • Best Image Competition
    • Nominate a Trainee Winner
  • Sponsorship
×

Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)

AdARRC™ December 27, 2021 Monday Weekly Update
 Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)

Question

Is fluvoxamine effective in preventing hospitalizations in high-risk adults with COVID-19?

Conclusion

In this study, compared with placebo, fluvoxamine decreased hospitalizations in high-risk symptomatic adults with COVID-19.

Reference

Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al, for the TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2021;S2214-109X(21)00448-4.

Share This Post!

Booster with Pfizer mRNA vaccine significantly reduces likelihood of infection and severe illness due to COVID-19 in adults 60+

Previous post

Evidence of benefit is lacking for low back pain relief with muscle relaxants

Next post

AdARRC™

Organising Secretariat

  • K.I.T. Group Middle East FZ LLC
  • Yas Creative Hub, Tower 1
  • P.O. Box: 77893
  • Abu Dhabi, United Arab Emirates

+ 971 2 245 0058
+ 971 55 295 0283
info@adarrc.org
Monday – Friday: 9:00 AM – 06:00 PM (GMT+4)

 

© 2026 AdARRC™. All rights reserved